Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.37 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12122049 | 1.00 | ELANE (0.37) | ELANEGPR142NTRK1LTA4HKMT2A | |
| SCHEMBL380277 | 0.96 | ELANE (0.35) | ELANENTRK1 | |
| SCHEMBL12122067 | 0.96 | ELANE (0.35) | ELANENTRK1 | |
| SCHEMBL380276 | 0.96 | ELANE (0.35) | ELANENTRK1 | |
| SCHEMBL381915 | 0.93 | ELANE (0.40) | ELANE | |
| SCHEMBL381046 | 0.93 | ELANE (0.40) | ELANE | |
| SCHEMBL1323856 | 0.92 | ELANE (0.33) | ELANEGPR142NTRK1 | |
| SCHEMBL12121987 | 0.92 | ELANE (0.33) | ELANEGPR142NTRK1 | |
| SCHEMBL1324444 | 0.92 | MAPT (0.38) | ELANENTRK1KMT2A | |
| SCHEMBL12122004 | 0.92 | HDAC6 (0.36) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | claimed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | claimed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048571-A1 | Organic Compounds | XIAP, BAX, MCL1 | ELANE 2481/4885GPR142 4350/4885NTRK1 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.